Advert - Theramex HQ UK Ltd – Case/0303/09/24

For the fundamental compliance errors highlighted by this case, including failing to provide up-to-date prescribing information for the Evorel (estradiol) range and Intrarosa (prasterone) for several years, Theramex HQ UK Ltd was publicly reprimanded by the Code of Practice Appeal Board. The Appeal Board had no evidence before it to show that Theramex had taken any action to improve since this case was reported to the Appeal Board by the Code of Practice Panel and considered by the Appeal Board in May 2025. By leaving the self-regulatory framework and requiring the MHRA to assume full responsibility for regulating it, Theramex has inevitably delayed any regulatory action and oversight. In addition to the public reprimand, the Appeal Board also required an audit of Theramex’s procedures in relation to the ABPI Code to be carried out by the PMCPA. Theramex must comply with the requirement for a PMCPA audit should it request to rejoin self-regulation in the future.